Evaluating minimally invasive surgery for early-stage ovarian cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the outcomes of patients with early-stage epithelial ovarian cancer who have undergone minimally invasive surgery, such as laparoscopic or robotic techniques. It aims to assess post-surgery complications, including rates of readmission and re-operation, as well as cancer outcomes like survival rates and the incidence of cancer upstaging. The study compares outcomes between patients treated with minimally invasive surgery and those who underwent traditional open surgery. By analyzing these two groups, the study seeks to provide insights into the effectiveness and safety of minimally invasive approaches for this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with apparent early-stage epithelial ovarian cancer at preoperative evaluation
2. Patients who underwent surgery between January 2014 and December 2023
3. Patients who underwent open or minimally invasive surgical staging (Laparoscopic or Robotic-assisted approach) or restaging procedure
4. Patients with final pathology report of Epithelial Ovarian Cancer

Exclusion Criteria:

1. Patients who have not performed a complete surgical staging
2. Patients who underwent neoadjuvant chemotherapy
3. Patients with invasive synchronous tumor
4. Patients with no informed consent
5. Patients with ASA class score of 4 or 5

Where it's running

• Ospedale Filippo del Ponte
  Varese, Varese, Italy Recruiting

Study contacts

• Study coordinator: Jvan Casarin, Medical Doctor
• Email: j.casarin@uninsubria.it
• Phone: +39 3335384990

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing nab-paclitaxel and solvent-based taxanes for advanced ovarian cancer treatment

  This study is testing if a new treatment called nab-paclitaxel, combined with carboplatin, is safer and more effective than standard treatments for people with advanced ovarian cancer.

  Recruiting Phase 3 Women's Hospital School Of Medicine Zhejiang University · Guangzhou, Guangdong and 10 other locations · NCT05737303

• VT-101 in Advanced Ovarian Cancer: early safety study in adults

  This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07905677

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• Whole-body metabolic activity as a predictor of chemotherapy response in epithelial ovarian cancer

  This study tests whether whole-body metabolic activity can predict how well epithelial ovarian cancer responds to chemotherapy.

  Recruiting University of Tennessee Graduate School of Medicine · Knoxville, Tennessee · NCT07764133

• [68Ga]BED003 PET imaging to see fibroblast activity in selected cancers

  This study tests a PET imaging agent, [68Ga]BED003, to see how well it detects tumors in colorectal, gastric, pancreatic, ovarian, and invasive lobular breast cancers.

  Recruiting at 5 sites Phase 2 Blue Earth Diagnostics · Bergamo, Lombardy and 5 other locations · NCT07702292

• Dual-target CAR-NK Cells for Peritoneal Cancers of the Ovary, Fallopian Tube, or Pseudoperitoneal Disease

  This trial tests a dual-target CAR-NK cell therapy for people with recurrent or hard-to-treat epithelial ovarian, fallopian tube, or primary peritoneal cancer who express two or more specific tumor markers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07617753

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.